Skip to content
10-Q

Quarterly Report

Eton Pharmaceuticals, Inc. ETON

0001437749-26-017064

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 27.39M sh
Shares Diluted Q1 2026 · Mar 31, 2026 31.55M sh
Shares Diluted Q1 2026 · Mar 31, 2025 26.89M sh
Capex Q1 2026 · Mar 31, 2026 $75K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 $7.41M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $2.09M
Long Term Debt Q1 2026 · Mar 31, 2026 $18.94M
Long Term Debt Q1 2026 · Dec 31, 2025 $21.77M
Short Term Debt Q1 2026 · Mar 31, 2026 $11.81M
Short Term Debt Q1 2026 · Dec 31, 2025 $8.79M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $19.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $25.94M
Stockholders Equity Q1 2026 · Mar 31, 2026 $30.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 $26.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $24.45M
Stockholders Equity Q1 2026 · Dec 31, 2024 $24.43M
Current Liabilities Q1 2026 · Mar 31, 2026 $44.18M
Current Liabilities Q1 2026 · Dec 31, 2025 $38.49M
Total Liabilities Q1 2026 · Mar 31, 2026 $67.1M
Total Liabilities Q1 2026 · Dec 31, 2025 $65.96M
Current Assets Q1 2026 · Mar 31, 2026 $53.25M
Current Assets Q1 2026 · Dec 31, 2025 $60.58M
Total Assets Q1 2026 · Mar 31, 2026 $97.71M
Total Assets Q1 2026 · Dec 31, 2025 $92.11M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.05
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.06
Eps Basic Q1 2026 · Mar 31, 2026 $0.06
Eps Basic Q1 2026 · Mar 31, 2025 −$0.06
Sga Expense Q1 2026 · Mar 31, 2026 $10.45M
Sga Expense Q1 2026 · Mar 31, 2025 $9.17M
Rd Expense Q1 2026 · Mar 31, 2026 $1.88M
Rd Expense Q1 2026 · Mar 31, 2025 $1.16M
Net Income Q1 2026 · Mar 31, 2026 $1.55M
Net Income Q1 2026 · Mar 31, 2025 −$1.57M
Operating Income Q1 2026 · Mar 31, 2026 $2.41M
Operating Income Q1 2026 · Mar 31, 2025 −$470K
Gross Profit Q1 2026 · Mar 31, 2026 $14.74M
Gross Profit Q1 2026 · Mar 31, 2025 $9.86M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $9.53M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $7.42M
Revenue Q1 2026 · Mar 31, 2026 $24.27M
Revenue Q1 2026 · Mar 31, 2025 $17.28M